News From Day 4
Sunday 8th October
Patient well-being symposium aims to raise awareness and offer solutions
The importance of considering the psychosocial and emotional impacts suffered by patients with diseases causing vision loss and the relationship between patient satisfaction with care and treatment adherence/persistence were topics
Delving into the distribution of retinal biomarkers for insights on disease aetiology and clinical features
Speakers in a Sunday morning symposium session presented their research investigating the spatial distribution of retinal biomarkers and discussed how the information provides insights about the etiology and clinical features
Session on age-related macular degeneration (AMD) covers topics relating to risk factor identification and treatment
Discussing the impact of genetic factors on AMD characteristics and natural history, Steffen Schmitz-Valckenberg (Germany) concluded that according to current knowledge, genetics appears to have a more relevant association with
Euretina General Assembly takes place
Attendees at the EURETINA General Assembly meeting on Sunday morning heard that Dr Anat Loewenstein (Israel) was elected as President Elect of the society by unanimous decision of the EURETINA
Speakers’ corner proving big hit with attendees
Delegates attending Saturday afternoon’s Speakers’ Corner session on imaging heard colleagues describe interesting cases and findings from prospective and retrospective clinical studies evaluating the performance of different imaging platforms for
ePoster winner: When oil strikes the macula
A study detailing the pros and cons of using silicone oil as a long-term tamponade agent after complex retinal surgery was the winner of the inaugural August Deutman prize for
RETINAWS: When the going gets tough, the tough get going
Delegates filling the Auditorium on Saturday morning for the RETINAWS video course were rewarded with a valuable learning experience as top surgeons from around the world presented and discussed video
Free Paper Winner: PULSAR trial shows efficacy of aflibercept 8 mg in wet AMD
The PULSAR trial in wet age-related macular degeneration demonstrated that aflibercept 8 mg administered every 12 or 16 weeks is noninferior in vision gains compared with aflibercept 2 mg every
Specialists delve deep to unravel retinal mysteries
Everybody loves a good detective mystery and retinal specialists are no exception. At the Medical Retina Mystery Cases session, the assembled audience was presented with a wide variety of puzzling
EVER Symposium: Defusing the ticking timebomb of high myopia
If current trends continue, one out of every two people on the planet will be myopic by the year 2050. Even more worryingly, a significant proportion of these will be
Charting EURETINA’s future: collaboration, standards, and cutting-edge research
Prof. Ramin Tadayoni, the incoming President of EURETINA, discusses the challenges and opportunities facing the Society over the next few years To what do you attribute the phenomenal growth of